News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vexim Again Awarded « Fastest Growing Listed Company » In The 2016 Technology Fast 50 For Southwestern France By Deloitte In Extenso



11/16/2016 10:11:49 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
TOULOUSE, France--(BUSINESS WIRE)--Regulatory News:

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announces that the company has again received the Award of the fastest growing listed company in the 2016 Technology Fast 50 for Southwestern France by Deloitte In Extenso.

Created by Deloitte France in 2001, the Technology Fast 50 extends to all regions in France and showcases the contributions of high-tech companies in boosting economic growth.

VEXIM again stood out for its excellent performance, with an increase in revenue of 404% from 2012 to 2015, representing a growth of +11 132K€ over the period.

As of September, 30th 2016, VEXIM achieved a cumulated revenue (9 months) of €13 265K, a significant increase of +37% compared with the same period in 2015 reflecting VEXIM’s strong performance on all its European and international markets. VEXIM has now become a key player on the spine trauma market: as of September, 30th 2016, the total number of implants sold since the launch of the SpineJack® in 2011 came over 38,150 units, representing approximately 18,175 patients treated.

“For the second consecutive time, Deloitte In Extenso Technology Fast 50 rewards VEXIM’s strong performance and dynamism. This is the result of our team’s efforts and I would like to thank all our employees for their dedicated work, as well as our partners and investors who actively support VEXIM’s development and are all part of this success”, commented Vincent Gardès, VEXIM’s CEO.

“The Technology Fast 50 showcases companies shaping the tremendous drive for innovation and value creation of French entrepreneurs, just like VEXIM. The Technology Fast 50 is already over its 16th edition and has become a standard for French and international investors. We are proud to have VEXIM among our 2016 recipients”, declared Laurent Halfon, Deloitte Partner National Head of the Technology Fast 50 Ranking.

Financial reporting schedule: 2016 sales results: January 17th, 20171

About the Technology Fast 50

The Technology Fast 50 was created in 1995 in San Jose (California), in the heart of the Silicon Valley, and was then extended to all the United-States and to the United-Kingdom, Canada, Netherlands, Israel and France. It has now expanded to more than 40 countries and regions in the world and showcases the contributions of high-tech companies in boosting economic growth.

Deloitte has also developed 3 continental rankings: Europe, Middle-East and Africa: Fast 500 EMEA

North America: Fast 500 North America

Asia Pacific: Fast 500 Asia Pacific

For further information: http://www.fast50france.com/

About VEXIM, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital2 and from BPI public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The company also developed the MasterflowTM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure. The company counts 64 employees, including its own sales teams in Europe and a network of international distributors. VEXIM has been listed on Alternext Paris since May 2012. For further information, please visit www.vexim.com

SpineJack® 3, a revolutionary implant for treating Vertebral Fractures

The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spinal surgery and worldwide patent protection through to 2029.

MasterflowTM 2, a high-performance orthopedic cement delivery system

The MasterflowTM is an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure for treating vertebral compression fractures. The device provides a better control of the injection of biomaterials into the spine. A complement of the SpineJack®, the MasterflowTM stands out for being both easy to use and precise, particularly in its ability to stop the cement delivery instantly without inertia. The MasterflowTM contributes to reducing pain in patients. Its first sales were recorded in the U.S. in February 2015, and the system has also received the CE marking in February 2015, a mandatory conformity mark for products marketed in Europe.

Name : VEXIM

ISIN code : FR0011072602

Ticker : ALVXM

1 Indicative date, subject to changes.

2 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

3 This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Read at BioSpace.com


comments powered by Disqus
Vexim
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES